Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Other Working Capital Changes (2016 - 2025)

Amicus Therapeutics' Other Working Capital Changes history spans 16 years, with the latest figure at $595000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Other Working Capital Changes fell 95.83% year-over-year to $595000.0, compared with a TTM value of $1.4 million through Dec 2025, up 109.9%, and an annual FY2025 reading of $1.4 million, up 109.9% over the prior year.
  • Other Working Capital Changes for Q4 2025 was $595000.0 at Amicus Therapeutics, up from -$7.6 million in the prior quarter.
  • The five-year high for Other Working Capital Changes was $15.0 million in Q4 2021, with the low at -$19.3 million in Q2 2024.
  • Average Other Working Capital Changes over 5 years is $379800.0, with a median of $856500.0 recorded in 2022.
  • Biggest YoY gain for Other Working Capital Changes was 1147.46% in 2023; the steepest drop was 3037.48% in 2023.
  • Tracing FOLD's Other Working Capital Changes over 5 years: stood at $15.0 million in 2021, then plummeted by 95.93% to $611000.0 in 2022, then plummeted by 3037.48% to -$17.9 million in 2023, then soared by 179.42% to $14.3 million in 2024, then tumbled by 95.83% to $595000.0 in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Other Working Capital Changes are $595000.0 (Q4 2025), -$7.6 million (Q3 2025), and $4.8 million (Q2 2025).